NextFin News - Pharming Group missed second-quarter expectations on both profit and revenue, but the more important signal was not the six-cent EPS shortfall or the $9.32 million sales miss. It was the guidance cut. The Dutch rare-disease company reported GAAP EPS of $0.00 versus a $0.06 estimate, revenue of $90.2 million versus a $99.52 million consensus, and then reduced full-year 2026 revenue guidance to $375 million-$395 million from $405 million-$425 million. In a business still trying to prove that Joenja can outrun RUCONEST’s decline, that is the kind of update that shifts the story from a one-quarter miss to a question about the shape of the next three quarters.
The quarter itself was mixed in the way earnings surprises often are when a company is in transition. Total revenue still rose 3% year over year, but the split exposed the strain inside the portfolio. RUCONEST revenue fell 10% to $72.3 million, while Joenja revenue rose 40% to $17.9 million. Pharming also said operating profit fell to $1.3 million from $10.8 million a year earlier, with the decline tied to lower revenue, manufacturing-related inventory impairments, and the planned closure of the production-support site in Évry, France. Those are not abstract adjustments. They are reminders that when a company’s largest product line softens, accounting noise and commercial execution both matter more.
What the market is really being asked to price now is not whether Pharming can still grow. It can. The question is whether the growth is still fast enough, and broad enough, to support the revenue path investors were previously assuming. The company’s own revision answers that question more cautiously than before. A midpoint cut of $30 million to full-year revenue guidance says management now expects the second half to do less heavy lifting than the market had hoped. That matters because investors usually tolerate a miss when the bridge to the next quarter is visible. Here, the bridge looks narrower.
Where The Miss Came From
Did Pharming miss because demand broke, or because the quarter was distorted by mix and timing? The answer is both, but the first-order signal is that the legacy franchise is still doing most of the work. RUCONEST represented about 80% of quarterly revenue at $72.3 million, which means the company’s quarterly trajectory still depends heavily on a product that is now declining year over year. Joenja is growing fast at 40%, but from a base of $17.9 million it is still too small to fully offset any meaningful RUCONEST slowdown.
That mix creates a familiar specialty-pharma mechanism. A legacy orphan-drug product reaches maturity, the newer product grows from a smaller base, and reported sales can still rise while investor confidence weakens because the composition of that growth is less durable than the headline suggests. The company can say total revenue increased 3% year over year, but if the older product is shrinking faster than the newer one scales, the market starts discounting the current growth rate as a bridge rather than a trend.
There is another layer to the story: Pharming did not just miss the quarter, it lowered the year. Full-year revenue guidance now centers on $385 million at the midpoint, versus $415 million before. That is not a trivial trim. It implies management sees a slower revenue run rate in the second half, even after accounting for Joenja growth, international expansion, and the first European launch in Germany after quarter-end. The company can still hit the revised range, but the range itself tells investors that the original pace was too optimistic.
“Updates 2026 total revenue guidance to US$375 million - US$395 million, reflecting a US$30 million reduction, and improves operating expense guidance by US$15 million to US$315 million - US$320 million.”
That guidance change is the most important line in the release because it converts a quarterly earnings miss into a forecast revision. Markets often forgive a miss when management can point to a temporary delay or a timing issue. They get less forgiving when the company proactively trims revenue expectations. The expense cut helps, but it does not change the basic message: the top line is now expected to grow more slowly than previously thought.
The same release also shows why the bull case is still alive. Pharming said Joenja revenue increased 40% to $17.9 million and that the first European launch in Germany came after quarter-end. The company also said it plans to report clinical data with leniolisib in larger CVID patient populations in the fourth quarter. That means the growth story has not ended; it has merely become more dependent on execution across multiple geographies and indications.
Is This A Cyclical Miss Or A Structural Reset?
The right answer is that the quarter is cyclical, but the underlying portfolio transition is structural. That distinction matters. The inventory impairments, the France site closure, and the quarter-to-quarter commercial timing effects can all create a cyclical wobble. Those effects can wash out over the next two reporting periods if specialty-pharmacy inventory normalizes and Joenja continues to expand internationally. But RUCONEST’s year-over-year decline points to a structural issue: the legacy product is no longer the kind of growth engine that can reliably carry the company on its own.
Why is that structural? Because the evidence is in the revenue composition, not just the quarterly variance. A business that still gets roughly four-fifths of revenue from one product has a concentrated earnings base. When that product declines 10% year over year while the younger product grows 40% from a much smaller base, the company is in a transition period whether the market wants to call it that or not. The market may have been pricing the transition as smoother than it is. This quarter suggests the bridge from RUCONEST to Joenja is still incomplete.
The transmission mechanism is straightforward. A weaker legacy product reduces revenue visibility, which compresses the market’s confidence in full-year guidance. Lower confidence raises the discount rate investors apply to the next growth phase, which in turn makes every future print more dependent on proof rather than promises. That second-order effect is more important than the first-order revenue miss because it changes the baseline for the next release. A quarter later, a routine beat may not be enough if it does not also show that Joenja is scaling faster than RUCONEST is fading.
“RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the second quarter 2025 and a 24% increase compared to the first quarter 2026, with active patient base 93% of year-ago and strong new patient enrollments.”
That sentence is the best argument against a bearish overreaction. The quarter-over-quarter rebound tells you the business did not collapse. The active patient base being 93% of year-ago levels also suggests the franchise remains alive and commercially relevant. But a franchise can remain alive and still stop being the primary source of upside. That is the tension the market is now forced to price.
The Strongest Bull Case, And The Signal That Breaks It
The strongest bullish argument is that this was a noisy quarter, not a broken trend. Pharming pointed to manufacturing-related inventory impairments, the closure of its Évry production-support site, and a first-half mix that still included growing Joenja sales. It also said Joenja’s U.S. and international momentum remains strong and that German commercialization began only after quarter-end. Under that view, the revenue miss is a timing issue, and the guidance cut mainly removes a layer of optimism that was never fully bankable.
That counter-thesis is credible because it fits the evidence that still looks constructive. Joenja is growing. RUCONEST rebounded sequentially. The company is still guiding to positive operating profit and has reduced operating expenses more than it reduced revenue, which suggests management is trying to protect margins while investing in the next growth phase. If the second half of 2026 delivers cleaner inventory patterns and incremental Joenja traction, the current miss may look like a temporary detour.
But the bullish case has a falsifying signal. If Pharming fails to show sequential revenue stabilization in the next two quarters, and if Joenja growth does not remain strong enough to offset any further RUCONEST erosion, then the “transition quarter” explanation loses force. A practical threshold would be revenue growth returning to a clearly positive sequential pattern and Joenja continuing to grow near or above 30% year over year. If that does not happen, the market will likely conclude that the transition is slower and more expensive than management implied.
That is the real test. The question is not whether one quarter missed by $9.32 million. It is whether the company can prove that a newer growth pillar is becoming large enough to absorb the decay in the older one.
What Investors Will Watch Next
Near term, the market will focus on whether the lowered 2026 revenue range proves conservative or becomes the new ceiling. The next quarterly update should clarify whether Joenja’s U.S. growth can extend into Europe and whether RUCONEST stabilizes after the second-quarter decline. Clinical catalysts also matter. Pharming said it plans to report leniolisib data in significantly larger CVID populations in the fourth quarter, and those readouts could help support the company’s long-term rare-disease thesis.
Over the medium term, the key issue is whether Pharming can build a balanced revenue base before the legacy franchise becomes an even bigger drag on growth rates. If Joenja keeps compounding and Germany becomes a meaningful launch market, the current miss may be remembered as a transition quarter. If RUCONEST keeps shrinking faster than Joenja scales, the market may decide the company’s growth profile has reset lower.
The base case is a slow but still intact transition: one legacy product softens, one newer product grows, and the company spends the rest of 2026 proving that the mix can improve without another guidance reset. The upside case is that Joenja’s momentum broadens across geographies and the lower revenue guide proves conservative. The downside case is that RUCONEST weakens again, Joenja remains too small to fully offset it, and the market treats this quarter as the start of a longer de-rating.
Pharming did not report a broken business. It reported a business whose next phase is still not large enough to hide the old one’s decline. That is a different problem, and a harder one.
Explore more exclusive insights at nextfin.ai.
